Cidara Therapeutics (CDTX) News Today $66.37 -1.12 (-1.66%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$66.87 +0.50 (+0.75%) As of 05:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Aberdeen Group plc Buys Shares of 120,879 Cidara Therapeutics, Inc. $CDTXAugust 24 at 4:07 AM | marketbeat.comComparing Cidara Therapeutics (NASDAQ:CDTX) and LakeShore Biopharma (NASDAQ:LSB)August 16, 2025 | americanbankingnews.comCidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b ReadoutAugust 15, 2025 | seekingalpha.comCidara Therapeutics: Promising Trials Amidst Financial ChallengesAugust 13, 2025 | msn.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of "Buy" from AnalystsAugust 11, 2025 | marketbeat.comCidara Therapeutics Reports Positive Trial Results and Financial GrowthAugust 9, 2025 | theglobeandmail.comCidara Therapeutics (CDTX) Receives a Buy from NeedhamAugust 9, 2025 | theglobeandmail.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Down - Here's WhyAugust 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, JMP Securities Analyst SaysAugust 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $74.00 at HC WainwrightAugust 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $74.00 at Needham & Company LLCAugust 9, 2025 | marketbeat.comVivo Capital LLC Grows Stock Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX)August 9, 2025 | marketbeat.comCidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comCidara (CDTX) Q2 Cash Surges 163%August 8, 2025 | theglobeandmail.comCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | finance.yahoo.comWest Michigan Advisors LLC Takes $291,000 Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX)August 6, 2025 | marketbeat.comCidara Therapeutics (CDTX) Projected to Post Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Reaches New 12-Month High - Here's WhyJuly 25, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Crosses Above 50 Day Moving Average - What's Next?July 25, 2025 | marketbeat.comCidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025July 24, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Sets New 52-Week High - What's Next?July 19, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Share Price Passes Above 50-Day Moving Average - Here's WhyJuly 16, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of "Buy" from BrokeragesJuly 16, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Down 7.6% - What's Next?July 15, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Trading 5.9% Higher - Still a Buy?July 14, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Sees Strong Trading Volume - Here's WhyJuly 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Down - Here's What HappenedJuly 8, 2025 | marketbeat.comSegal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara TherapeuticsJuly 7, 2025 | businesswire.comWarner Bros., Cidara, LENZ Therapeutics, and More Stocks See Action From Activist InvestorsJuly 3, 2025 | msn.comCidara Therapeutics (NASDAQ:CDTX) Sees Strong Trading Volume - What's Next?July 2, 2025 | marketbeat.comCidara Therapeutics Added to Russell 2000 and Russell 3000 Indexes Recognizing Corporate Progress - NasdaqJuly 2, 2025 | nasdaq.comCidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 1, 2025 | globenewswire.comInsider Buying: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Director Buys 2,272,727 Shares of StockJuly 1, 2025 | insidertrades.comRa Capital Management, L.P. Purchases 2,272,727 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) StockJune 30, 2025 | marketbeat.comBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (CDTX)With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?June 30, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Down 5% - Should You Sell?June 30, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Given "Market Outperform" Rating at JMP SecuritiesJune 30, 2025 | marketbeat.comCidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® IndexesJune 30, 2025 | globenewswire.comCidara Therapeutics Inc (CDTX) - Investing.com UKJune 29, 2025 | uk.investing.comCidara Therapeutics, Inc. (CDTX) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comCidara Therapeutics Closes Public Offering of 9.1 Million Shares, Raising $402.5 Million - NasdaqJune 27, 2025 | nasdaq.comCidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJune 26, 2025 | uk.finance.yahoo.comCidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesJune 26, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Sees Strong Trading Volume - Still a Buy?June 26, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Down - Time to Sell?June 25, 2025 | marketbeat.comCidara Therapeutics Advances CD388 To Phase 3, Reiterate BuyJune 25, 2025 | seekingalpha.comCidara Therapeutics prices upsized $350 milion stock offering at $44June 25, 2025 | msn.comCidara Announces Pricing of Upsized Public Offering of Common StockJune 24, 2025 | globenewswire.comCidara reports outcomes from trial of CD388 for preventing seasonal influenzaJune 24, 2025 | msn.com Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼1.790.71▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼14▲CDTX Articles Average Week Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rhythm Pharmaceuticals News Today Avidity Biosciences News Today Nuvalent News Today Axsome Therapeutics News Today CRISPR Therapeutics News Today Abivax News Today Merus News Today Cytokinetics News Today Viking Therapeutics News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access